Shares of Intrexon Corp (NYSE:XON) have been assigned an average recommendation of “Hold” from the ten ratings firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $34.71.
Several research analysts recently commented on the stock. Northland Securities reiterated a “buy” rating and issued a $17.00 target price on shares of Intrexon in a report on Friday, March 2nd. Bank of America dropped their target price on shares of Intrexon from $21.00 to $19.00 and set a “neutral” rating on the stock in a report on Friday, March 2nd. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $18.00 target price (down previously from $22.00) on shares of Intrexon in a report on Monday, March 5th. Zacks Investment Research upgraded shares of Intrexon from a “sell” rating to a “hold” rating in a report on Monday, January 22nd. Finally, ValuEngine downgraded shares of Intrexon from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st.
Intrexon (XON) traded up $0.93 during trading on Friday, hitting $16.75. 2,420,117 shares of the stock were exchanged, compared to its average volume of 1,473,269. The company has a market cap of $2,041.83, a P/E ratio of -17.09 and a beta of 1.30. The company has a quick ratio of 1.85, a current ratio of 1.92 and a debt-to-equity ratio of 0.01. Intrexon has a fifty-two week low of $10.26 and a fifty-two week high of $26.99.
In related news, CEO Randal J. Kirk purchased 1,000,000 shares of the firm’s stock in a transaction on Friday, January 19th. The shares were bought at an average cost of $12.50 per share, for a total transaction of $12,500,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 55.10% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Third Security LLC boosted its position in shares of Intrexon by 2.5% during the 4th quarter. Third Security LLC now owns 57,928,289 shares of the biotechnology company’s stock valued at $667,334,000 after acquiring an additional 1,423,236 shares in the last quarter. Iridian Asset Management LLC CT boosted its position in Intrexon by 22.5% in the fourth quarter. Iridian Asset Management LLC CT now owns 4,518,112 shares of the biotechnology company’s stock valued at $52,049,000 after buying an additional 828,368 shares in the last quarter. BlackRock Inc. boosted its position in Intrexon by 5.9% in the fourth quarter. BlackRock Inc. now owns 2,563,111 shares of the biotechnology company’s stock valued at $29,528,000 after buying an additional 142,915 shares in the last quarter. First Trust Advisors LP boosted its position in Intrexon by 41.5% in the fourth quarter. First Trust Advisors LP now owns 2,248,411 shares of the biotechnology company’s stock valued at $25,902,000 after buying an additional 659,632 shares in the last quarter. Finally, Peregrine Capital Management LLC boosted its position in Intrexon by 10.7% in the fourth quarter. Peregrine Capital Management LLC now owns 645,596 shares of the biotechnology company’s stock valued at $7,437,000 after buying an additional 62,268 shares in the last quarter. Institutional investors and hedge funds own 76.84% of the company’s stock.
Intrexon Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.